{"id":"fixed-duration-dexamethasone","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Increased infection risk"},{"rate":null,"effect":"Mood changes"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Osteoporosis (with prolonged use)"}]},"_chembl":{"chemblId":"CHEMBL1697787","moleculeType":"Small molecule","molecularWeight":"528.57"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexamethasone is a synthetic glucocorticoid that acts as an agonist at the glucocorticoid receptor, leading to transrepression of pro-inflammatory genes and transactivation of anti-inflammatory genes. The 'fixed-duration' formulation likely refers to a predetermined treatment course designed to minimize long-term corticosteroid exposure while maintaining therapeutic benefit. This approach aims to reduce cumulative adverse effects associated with prolonged corticosteroid use.","oneSentence":"Dexamethasone is a corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors and modulating gene expression.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:40.880Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and immune-mediated conditions (specific indication under investigation in phase 3 trial not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT06182774","phase":"PHASE3","title":"Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2024-04-10","conditions":"Multiple Myeloma","enrollment":570},{"nctId":"NCT07463807","phase":"PHASE1, PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":162},{"nctId":"NCT03386617","phase":"PHASE2","title":"AKY15-HK-301_NEPA Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2018-02-27","conditions":"Breast Cancer","enrollment":55},{"nctId":"NCT05440851","phase":"NA","title":"Platform of Randomized Adaptive Clinical Trials in Critical Illness","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-04-30","conditions":"Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High","enrollment":6250},{"nctId":"NCT02861573","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-11-17","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":1200},{"nctId":"NCT03020030","phase":"PHASE3","title":"Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-03","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":560},{"nctId":"NCT07280780","phase":"","title":"CGM-Based Glycemic Analysis After ESI","status":"NOT_YET_RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2025-12-18","conditions":"Type 2 Diabetes (T2DM), Hyperglycemia, Radicular Pain","enrollment":36},{"nctId":"NCT06200168","phase":"PHASE3","title":"Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2024-01-16","conditions":"Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting","enrollment":370},{"nctId":"NCT03836014","phase":"PHASE3","title":"Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-07-25","conditions":"Multiple Myeloma in Relapse","enrollment":436},{"nctId":"NCT05203003","phase":"","title":"Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-04-22","conditions":"Multiple Myeloma","enrollment":260},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04462523","phase":"PHASE4","title":"DEXTENZA for the Treatment of Postoperative Pain and Inflammation Following Vitreo-retinal Surgery","status":"COMPLETED","sponsor":"Patrick R. Oellers, MD","startDate":"2020-01-03","conditions":"Vitreo-Retinal Surgery","enrollment":40},{"nctId":"NCT02336815","phase":"PHASE2","title":"Selinexor Treatment of Refractory Myeloma","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-05-26","conditions":"Multiple Myeloma","enrollment":202},{"nctId":"NCT05658692","phase":"PHASE4","title":"Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-10-01","conditions":"Acute Respiratory Distress Syndrome","enrollment":1000},{"nctId":"NCT02042391","phase":"PHASE2","title":"Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy","status":"COMPLETED","sponsor":"Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH","startDate":"2015-02-03","conditions":"Posttransplant Lymphoproliferative Disorder","enrollment":60},{"nctId":"NCT04492501","phase":"NA","title":"Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan","status":"COMPLETED","sponsor":"UNICEF","startDate":"2020-04-01","conditions":"Covid19, Cytokine Release Syndrome, Critical Illness","enrollment":600},{"nctId":"NCT02625181","phase":"NA","title":"Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2016-07","conditions":"Postoperative Nausea and Vomiting","enrollment":27034},{"nctId":"NCT03518463","phase":"NA","title":"Enhanced Recovery After Surgery for Emergency Caesarean Deliveries","status":"COMPLETED","sponsor":"Mbarara University of Science and Technology","startDate":"2017-06-20","conditions":"Pregnancy Related","enrollment":160},{"nctId":"NCT00135811","phase":"PHASE3","title":"Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2004-11","conditions":"Glomerulosclerosis, Focal","enrollment":207}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fixed-duration dexamethasone","genericName":"Fixed-duration dexamethasone","companyName":"UMC Utrecht","companyId":"umc-utrecht","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexamethasone is a corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors and modulating gene expression. Used for Inflammatory and immune-mediated conditions (specific indication under investigation in phase 3 trial not publicly detailed).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}